Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Growing year on year, the flagship 10th annual 2018 Pre-Filled Syringes Europe conference already attracted an international audience from Austria, Belgium, Denmark, France, Germany, Italy ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We read all day so you don't have to. Sign up for CNN Business' newsletter for the top stories you need to know.